We suggest that the synaptamide-induced inhibition of neuroinflammatory processes, preventing hyperstimulation of glutamate receptors and LTP disruption through the maintenance of NMDAR1 levels, normalizes immediate-early gene expression and reverse long-term memory impairments. The gene discussed is GRIN1; the disease is memory.